Business
BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
SAN CARLOS, Calif., January 13, 2026--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will outline the pillars of its growing global oncology leadership during its presentation today at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
About this update from Jp Morgan Chase & Co.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":28492,"height":5743,"url":"https://media.zenfs.com/en/business-wire.com/9ce7fc74647525e5274fad5ebca7f6bb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/x7nQvO3RThZT965slsweNw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/9ce7fc74647525e5274fad5ebca7f6bb","width":960,"height":194},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/H71VScJ9C4jMSi5WWVwRBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00ODQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/9ce7fc74647525e5274fad5ebca7f6bb","width":1200,"height":242}},"lazy":false},{"type":"text","content":"Company outlines foundational hematology leadership, multiple 2026 data catalysts, a unique global clinical development superhighway, and continued financial excellence","length":168,"tagName":"p","attribs":{}},{"type":"text","content":"SAN CARLOS, Calif., January 13, 2026--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will outline the pillars of its growing global oncology leadership during its presentation today at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.","length":311,"tagName":"p"},{"type":"text","content":"John V. Oyler, Co-Founder, Chairman, and CEO at BeOne, will highlight the Company’s transformative leadership in treating B-cell malignancies. The presentation will feature BRUKINSA®, the global leader among Bruton’s tyrosine kinase (BTK) inhibitors, as well as foundational hematology assets: sonrotoclax, a next-generation and potentially best-in-class B-cell lymphoma 2 (BCL2) inhibitor that received its first global regulatory approvals on December 30, and BGB-16673, a potentially first-in-class and best-in-class BTK chimeric degradation activation compound (CDAC). In addition, Mr. Oyler will share further information on BeOne’s global development superhighway, which encompasses global, wholly internal, and competitively advantaged clinical capabilities that can greatly reduce the cost and time to develop a new medicine, thereby increasing the speed of access to innovation for patients around the world.","length":917,"tagName":"p"},{"type":"text","content":""BeOne is emerging as the world’s leading ...